TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05890352
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05890352
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06004856
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib once daily (QD)
Study: NCT04948203
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Triangular-shaped tablet
Study: NCT05718843
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809
Study: NCT06665633
Drug: Oxygen 100 % Gas for Inhalation
Normalized name: oxygen 100 % Gas for Inhalation
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen 100% Gas for Inhalation in Hyperbaric Oxygen Therapy Chamber at 1.5 ATA
Study: NCT05807659
Drug: fractionated busulfan-based conditioning regimen
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine~1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation
Study: NCT06665997
Drug: Depot medroxyprogesterone acetate (DMPA)
Normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension
Study: NCT00002059
Drug: Inosine pranobex
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04713592
Drug: Placebo for Risankizumab
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (SC) Injection
Study: NCT04713592
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (SC) Injection
Study: NCT06512207
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor
Study: NCT05352672
Drug: Fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT05352672
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT05352672
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT06664138
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam is a recently approved medication used for the induction of general anesthesia and maintenance of sedation. There have been no prior studies using remimazolam for the induction of anesthesia in ECT, and this research aims to investigate the feasibility of using remimazolam as an induction agent for ECT.
Study: NCT06664138
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate is widely used in ECT due to its rapid onset, stable hemodynamic profile, and quick recovery. In this study, remimazolam will be used as the experimental group, while etomidate will serve as the control group.
Study: NCT05160532
Drug: Dextrose prolotherapy (DPT)
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% dextrose, mixing 2.5ml of sterile water and 2.5ml of 50% dextrose.
Study: NCT06451562
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a local anesthetic drug of the amino amide type
Study: NCT06667024
Drug: Hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only
Study: NCT06667024
Drug: Dexmedetomidine and Hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient height) hyperbaric bupivacaine
Study: NCT06174298
Drug: Granulocyte Colony-Stimulating Factor (Filgrastim)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intervention Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.
Study: NCT05640726
Drug: PD-1
Normalized name: NPD-1
DrugBank: PD-168393 (DB07662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
Study: NCT05640726
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 of every 2 weeks
Study: NCT05640726
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Oxaliplatin，85mg/m2，day1
Study: NCT05640726
Drug: Calcium folinate
Normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive calcium folinate ，400mg/m2，day1
Study: NCT05640726
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 5-fluorouracil ，400mg/m2，day1
Study: NCT06700070
Drug: PBA-0111
Normalized name: PBA
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral microdose injection by the CIVO device.
Study: NCT05098119
Drug: Sintilimab, Nab-paclitaxel, Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant Therapy
Study: NCT05098119
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Therapy
Study: NCT05848492
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole will be given for prevention of invasive candidiasis in preterm and very low birthweight babies.
Study: NCT05848492
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% Saline 2cc intravenous will be given to preterm babies in placebo group.
Study: NCT05257824
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. short-term dual antiplatelet: dual antiplatelet agents for 6 months~2. long-term dual antiplatelet: dual antiplatelet agents for 12 months
Study: NCT05257824
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1. short-term dual antiplatelet: dual antiplatelet agents for 6 months~2. long-term dual antiplatelet: dual antiplatelet agents for 12 months
Study: NCT05581303
Drug: Olpasiran
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran given by subcutaneous injection Q12W.
Study: NCT05413369
Drug: Insulin glargine/Lixisenatide
Normalized name: INSULIN GLARGINE/LIXISENATIDE
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: solution, by subcutaneous injection
Study: NCT05413369
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, orally
Study: NCT05413369
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, orally
Study: NCT05431023
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection
Study: NCT06613854
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide Oral Tablets will be introduced to the Oral Semaglutide Arm as per protocol for regular therapy introduction.
Study: NCT06613854
Drug: Empagliflozin 10 mg
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin Oral Tablets will be introduced to the Empagliflozin Arm as per protocol for regular therapy introduction.
Study: NCT06016010
Drug: USL
Normalized name: USL-311
DrugBank: USL-311 (DB15265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg of Achyranthis Radix Extract
Study: NCT04738097
Drug: Ticagrelor 90mg
Normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.Treatment will be continue with ASA 80 until 3 months.
Study: NCT04738097
Drug: Clopidogrel 75 mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.Treatment will be continue with ASA 80 until 3 months.
Study: NCT06698666
Drug: Sertraline Pill
Normalized name: sertraline Pill
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both control and intervention group will receive the sertraline as a standard therapy
Study: NCT06699394
Drug: Teclistamab (Tec)
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab is administered subcutaneously with the usual step-up dosing: 0.06 mg/kg at day 1, 0.3 mg/kg at day 4, 1.5 mg/kg at day 8, and then 1.5 mg/kg weekly.
Study: NCT05743101
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
Study: NCT05743101
Drug: Levofloxacin simulant
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin simulant is placebo.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
Study: NCT06034938
Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
Normalized name: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Switch previous therapy with DOR/TDF/3TC
Study: NCT00063791
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000861
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05300802
Drug: Dexmedetomidine Hcl 100 Mcg/mL Inj
Normalized name: dexmedeTOMIDine HCl 100 MCG/ML Injectable Solution
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.
Study: NCT05300802
Drug: Dexmedetomidine Hcl 100 Mcg/mL Inj
Normalized name: dexmedeTOMIDine HCl 100 MCG/ML Injectable Solution
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.
Study: NCT06065813
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Toripalimab intravenously every 3 weeks 3 doses of Toripalimab before operation 14 doses of Toripalimab 30 days after operation
Study: NCT06698861
Drug: Neulasta (Amgen)
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose of Neulasta will be given SC injection at 6 mg in Cohort 2b.
Study: NCT06631521
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg (two 300 mg tablets) taken orally twice daily.
Study: NCT06631521
Drug: Relugolix
Normalized name: Relugolix
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A loading dose of 360 mg on the first day, followed by 120 mg taken orally once daily.
Study: NCT06554509
Drug: SHR-1819 injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1819 injection
Study: NCT05453435
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 6 months after completing CD20 monoclonal antibody therapy.
Study: NCT06111196
Drug: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/4ml;single dose;intravenous injection
Study: NCT06111196
Drug: Pembrolizumab injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/4ml;single dose;intravenous injection
Study: NCT05484349
Drug: Tizanidine Hydrochloride
Normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine Hydrochloride 1 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
Study: NCT05484349
Drug: Tizanidine Hydrochloride
Normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine Hydrochloride 2 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
Study: NCT05484349
Drug: Tizanidine Hydrochloride Placebo
Normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine Hydrochloride Placebo Comparator 1 tablet Tid for 12 consecutive weeks and were followed up for 12 weeks
Study: NCT06152497
Drug: H1 blockade: Telfast: 180mg Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H1 blockade: oral blockade with 180mg Fexofenadine
Study: NCT06684951
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: observe hCG effect on endometrial receptivity
Study: NCT05127304
Drug: Furoate/Umeclidinium/Vilanterol
Normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furoate/Umeclidinium/Vilanterol
Study: NCT05127304
Drug: Tiotropium Bromide/Olodaterol
Normalized name: tiotropium bromide/olodaterol HCl 2.5 mcg-2.5 mcg/actuation INHALATION MIST INHALER (GRAM)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Bromide/Olodaterol
Study: NCT05556200
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight \<50 kg)
Study: NCT04784988
Drug: EHL-FVIII
Normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: prophylaxis with EHL-FVIII targeting a 12% FVIII through level based on PK assessment with WAPPS-Hemo
Study: NCT04784988
Drug: FVIII concentrate
Normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard prophylaxis with FVIII concentrate according to current guidelines
Study: NCT06140888
Drug: Ginkgo Biloba Extract
Normalized name: Ginkgo biloba extract
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract 8 pills three times per day is administrated.
Study: NCT04021121
Drug: LZD
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LZD 1200 mg daily
Study: NCT04021121
Drug: High dose RIF
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIF 35 mg/kg/day
Study: NCT05423197
Drug: 89Zr-panitumumab IV
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions
Study: NCT05423197
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 30mg will be given orally
Study: NCT05104801
Drug: sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitravatinib 100mg QD PO
Study: NCT05104801
Drug: tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tislelizumab 200mg Q3W IV
Study: NCT06419543
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Observe the incidence of paradoxical reactions after the first induction.
Study: NCT06452147
Drug: Intravenous lidocaine+standard anesthesia
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Subjects randomly assigned to Lidocaine Group (Group L) will be given ECG monitoring, oxygen saturation monitoring, blood pressure monitoring and an open intravenous route on the morning of the surgery. It is recommended to start the infusion of Lidocaine as soon as possible in the ward.~2. It is recommended to use portable electronic infusion pump for drug delivery. The loading dose is 1mg/kg, and the maintenance dose range is 1\~2mg/kg/h. The specific dosage is determined by the anesthesiologist based on the patient's condition. The infusion ends when the patient leaves the Post-anesthesia care unit after surgery, and the infusion time and total amount should be recorded.
Study: NCT06452147
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.33% bupivacaine liposome
Study: NCT06520982
Drug: Isoproterenol
Normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infused intra-arterially in a dose-response fashion
Study: NCT06520982
Drug: Nitroprusside
Normalized name: Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infused intra-arterially in a dose-response fashion
Study: NCT06520982
Drug: Estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infused intra-arterially
Study: NCT05507476
Drug: Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery.
Study: NCT06666621
Drug: Normal saline infusion
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After assessment of response to lumbar medial branch block, 8 ml normal saline will be infused through IV over several minutes. 10 minutes will pass, and response to lumbar medial branch block procedure will be re-assessed.~After this step, naloxone infusion will occur (see next intervention)
Study: NCT06666621
Drug: Naloxone infusion
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After infusion of normal saline and re-assessment of response to lumbar medial branch block procedure, 8 milligrams of naloxone will be infused over several minutes. Then after 10 minutes, response to lumbar medial branch block procedure will be re-reassessed for the final time.
Study: NCT04654988
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months
Study: NCT04654988
Drug: Placebo Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo Prednisone
Study: NCT05488509
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will inhale vapor from cannabis containing either 20mg THC or 40mg THC.
Study: NCT05219266
Drug: midostaurin
Normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients receive midostaurin
Study: NCT00002180
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05523011
Drug: Exosome ointment
Normalized name: Stem-cell derived exosome vesicle products
DrugBank: Stem-cell derived exosome vesicle products (DB15743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg MSC exosomes/g ointment